You are here

Samsung's drug-making unit soars on market debut

Seoul

SHARES in Samsung's drug-making unit soared almost six per cent on their market debut on Thursday, after one of South Korea's biggest ever initial public offerings that raised nearly US$2 billion.

Samsung Biologics, a contract manufacturer of biotech drugs for global

sentifi.com

Market voices on:

Powered by GET.comGetCom